Secarna - About the company
Secarna is an unfunded company based in Planegg (Germany), founded in 2015 by Jonas Renz. It operates as a Developer of oligonucleotide therapies to treat disorders related to immuno-oncology and ophthalmology. Secarna has not raised any funding yet. The company has 118 active competitors, including 36 funded and 43 that have exited. Its top competitors include companies like Odyssey, NextCure and Compass Therapeutics.
Company Details
Secarna is developing oligonucleotide therapies to treat disorders related to immuno-oncology and ophthalmology. They have developed their own proprietary drug discovery platform, LNAplus, where it uses RNase H1, a cellular enzyme, and target RNA (mRNA) to suppress the expression of encoded proteins. Their lead candidate, PD-L1, is in the preclinical stage, used for treating cancer.
- Website
- www.secarna.com/
- Email ID
- *****@secarna.com
- Phone Number
- +49 **********
Key Metrics
Founded Year
2015
Location
Planegg, Germany
Stage
Unfunded
Ranked
28th among 118 active competitors
Employee Count
17 as on Aug 31, 2026
Sign up to download Secarna's company profile
Secarna's funding and investors
Secarna has not raised any funding rounds yet.
Secarna's founders and board of directors
Founder? Claim ProfileThe founders of Secarna is Jonas Renz.
Here are the details of Secarna's key team members:
- Jonas Renz: Co-Founder & MD of Secarna.
View details of Secarna's Founder profiles and Board Members
Secarna's employee count trend
Secarna has 17 employees as of Aug 26. Here is Secarna's employee count trend over the years:
Uncover Secarna's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Secarna's Competitors and alternates
Top competitors of Secarna include Odyssey, NextCure and Compass Therapeutics. Here is the list of Top 10 competitors of Secarna, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Odyssey 2018, Cambridge (United States), Public | Developer of immunotherapeutics for immunological and cancer diseases | $717M | 66/100 | |
2nd | NextCure 2015, New Haven (United States), Public | Developer of next-generation immuno-oncology-based drugs | $175M | 66/100 | |
3rd | Compass Therapeutics 2013, Cambridge (United States), Public | Antibody discovery and development company | $239M | 65/100 | |
4th |  Eureka Therapeutics 2006, Emeryville (United States), Series E | Biopharmaceutical firm pioneering T-cell therapies for solid tumors and malignancies | $176M | 62/100 | |
5th | AgomAb Therapeutics 2017, Ghent (Belgium), Public | Developer of monoclonal antibody molecules for multiple disorders | $327M | 61/100 | |
6th | Innate Pharma 1999, Marseille (France), Public | Developer of antibody based therapeutics to treat cancer | $43.5M | 61/100 | |
7th | Allakos 2012, San Mateo (United States), Public | Develop therapeutic antibodies for the treatment of allergic, inflammatory, and proliferative diseases | $160M | 60/100 | |
8th | Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders | $69.7M | 59/100 | ||
9th | Y-mAbs Therapeutics 2014, New York City (United States), Acquired | Provider of antibodies-based products targeting GD2 and B7H3 tumor antigens. | $90M | 59/100 | |
10th | Developer of antibody therapeutics for the treatment of cancer and autoimmune diseases | - | 58/100 | ||
28th | Developer of oligonucleotide therapies to treat disorders related to immuno-oncology and ophthalmology | - | - | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Secarna's competitors? Click here to see the top ones
Secarna's Investments and acquisitions
Secarna has made no investments or acquisitions yet.
Reports related to Secarna
Here is the latest report on Secarna's sector:
News related to Secarna
Filter this listMedia has covered Secarna for a total of 4 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.
•
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) AllianceGlobeNewswire•Aug 24, 2026•VERAXA, Secarna
•
•
Protalix Bio and Secarna Pharma Announce Collaboration and Option AgreementPR Newswire•Dec 17, 2025•Protalix BioTherapeutics, Secarna
•
Secarna and Vect-Horus Collaborate to Advance RNA-Targeted Therapies for CNS DisordersWebDisclosure•Jul 10, 2025•Secarna, Vect-Horus
•
Secarna and Vect-Horus collaborate on targeted RNA therapies for CNS diseasesGlobeNewswire•Jul 10, 2025•Secarna, Vect-Horus
•
CD39 therapies: Market analysis predicts first approval by 2029.Business Wire•Jan 31, 2025•Innate Pharma, AstraZeneca, Secarna, Biotheus and 8 others
•
•
•
Celanese and Secarna Pharmaceuticals enter into RNA research collaborationSeeking Alpha•Mar 20, 2024•Secarna, Celanese
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Secarna
Explore our recently published companies
- Sigma Media Group - Tulsa based, Unfunded company
- uTrending - Unfunded company
- Brandfolder - Boulder based, 2013 founded, Unfunded company
- Addis AI Enterprise - Orpund based, Unfunded company
- Cyberward AI - United States based, Unfunded company
- Crystal AI - Palo Alto based, 2018 founded, Unfunded company
